[HTML][HTML] MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress

M Felder, A Kapur, J Gonzalez-Bosquet, S Horibata… - Molecular cancer, 2014 - Springer
Over three decades have passed since the first report on the expression of CA125 by
ovarian tumors. Since that time our understanding of ovarian cancer biology has changed …

[HTML][HTML] Potential role of peptidylarginine deiminase enzymes and protein citrullination in cancer pathogenesis

S Mohanan, BD Cherrington, S Horibata… - Biochemistry research …, 2012 - hindawi.com
… Furthermore, treatment of the pituitaryderived MtT/S cell line with estrogen results in a
dosedependent increase in PAD expression and activity [42]. Together, these observations …

[HTML][HTML] Identification of macrophage extracellular trap-like structures in mammary gland adipose tissue: a preliminary study

S Mohanan, S Horibata, JL McElwee… - Frontiers in …, 2013 - frontiersin.org
… For IHC, slides were incubated in DAB chromagen (Vector Labs) solutions according to
the manufacturer’s protocol, washed and then counterstained with Gill’s hematoxylin, and …

[HTML][HTML] Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes

…, S Horibata, GAA Jennifer, S Petrie, A Kapur, S André… - Molecular cancer, 2010 - Springer
Background MUC16 is a cell surface mucin expressed at high levels by epithelial ovarian
tumors. Following proteolytic cleavage, cell surface MUC16 (csMUC16) is shed in the …

[HTML][HTML] MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells

…, S Horibata, JA Belisle, A Kapur, H Holden, S Petrie… - Molecular cancer, 2010 - Springer
Background Cancer cells utilize a variety of mechanisms to evade immune detection and
attack. Effective immune detection largely relies on the formation of an immune synapse which …

Hematopoietic stem cell–engrafted NOD/SCID/IL2Rγnull mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral …

S Watanabe, K Terashima, S Ohta, S Horibata… - Blood, 2007 - ashpublications.org
Critical to the development of an effective HIV/AIDS model is the production of an animal
model that reproduces long-lasting active replication of HIV-1 followed by elicitation of virus-…

Utilization of the soft agar colony formation assay to identify inhibitors of tumorigenicity in breast cancer cells

S Horibata, TV Vo, V Subramanian… - JoVE (Journal of …, 2015 - jove.com
… The soft agar assay on the other hand is distinct from 2D culture systems because it quantifies
tumorigenicity by measuring a cell’s ability to proliferate and form colonies in suspension …

[PDF][PDF] A proteome-wide fission yeast interactome reveals network evolution principles from yeasts to human

…, LG Liu, A Matsuyama, M Trickey, S Horibata… - Cell, 2016 - cell.com
… network than it is to that of S. cerevisiae. Furthermore, among … with the proteomewide
interactome of S. cerevisiae, we are … by 4,989 S. pombe genes (corresponding to > 99% of all …

Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor–resistant cancer

N Gupta, TT Huang, S Horibata, JM Lee - Pharmacological research, 2022 - Elsevier
… Double-stranded breaks (DSBs) accompanied by PARP trapping strongly blocks
replication and induces S phase checkpoints, resulting in further DNA breaks and cytotoxicity, …

[HTML][HTML] Mechanisms of chemotherapy resistance in ovarian cancer

M Ortiz, E Wabel, K Mitchell, S Horibata - Cancer Drug Resistance, 2022 - ncbi.nlm.nih.gov
… generated the figure; Wabel E wrote the paclitaxel and bevacizumab resistance mechanism
and generated the figure; Mitchell K wrote the platinum resistance mechanisms; Horibata S